Association between pre-diabetes or diabetes and cognitive impairment in a -community dwelling older population: Bushehr Elderly Health (BEH) program

Association between pre-diabetes or diabetes and cognitive impairment in a -community dwelling older population: Bushehr Elderly Health (BEH) program | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Association between pre-diabetes or diabetes and cognitive impairment in a -community dwelling older population: Bushehr Elderly Health (BEH) program Sara Farkhani, Moloud Payab, Farshad Sharifi, Yasaman Sharifi, and 10 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1658783/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 18 Oct, 2023 Read the published version in Journal of Diabetes & Metabolic Disorders → Version 1 posted You are reading this latest preprint version Abstract Background Uncontrolled hyperglycemia is one of the risk factors for cognitive disorders. By this finding, both type 1 and type 2 diabetes may predispose to cognitive impairment in poorly controlled cases. The current large-scale study is aimed at cognitive impairments in diabetic and non-diabetic older adults separately. Methods This is a cross-sectional study from phase 2 of the Bushehr elderly health program (BEHP). Mini-cog and categorical verbal fluency tests (CFTs) were used to assess cognitive function. Patients were classified as non-diabetics, pre-diabetics, or diabetics based on the diagnostic criteria for diabetes mellitus (DM). To compare the means of the two groups, we used the t-test or the Mann-Whitney test. Multivariable logistic regression models were also used to determine the association between pre-diabetes or DM and cognitive impairment. Results Six hundred and ninety-three (45.2%) out of 1533 participants were ascertained to be cognitively impaired. The average hemoglobin A1C was higher in diabetic patients with cognitive impairment compared to those without cognitive impairment. (5.8 ± 1.6% vs. 5.5 ± 1.4%, P = 0.004). Besides, the mean blood glucose levels were found to be more elevated in cognitively impaired cases (108.0 ± 47.4 mg/dL vs. 102.1 ± 0.35 mg/dL, P = 0.002). After adjusting for age, gender, body mass index(BMI), waist circumference, amount of physical activity, and smoking, the multivariable logistic regression model, declared an association between diabetes and cognitive impairment (OR = 1.48, P = 0.003). Older patients, females, widows, and patients with elevated LDL-Cs and blood pressure are also more vulnerable to cognitive impairment. Conclusion In the BEHP, there is a positive association between cognitive impairment and DM, notably in long-term, poorly controlled cases, whereas no association was found among pre-diabetics in our elderly study populations. Pre-diabetes Diabetes Cognitive Impairment Aged Figures Figure 1 Introduction Diabetes and cognitive disorders have become more prevalent in the last decade as a result of lifestyle and demographic changes[ 1 ]. Dementia is a clinical syndrome characterized by progressive declines in cognitive and functional ability [ 2 ]. It is estimated that approximately 50 million people worldwide suffer from dementia, with the figure expected to nearly double every 20 years to approximately 115 million by 2050.[ 3 ]. According to the 2015 diabetes prevalence figures, approximately 415 million people worldwide suffer from diabetes. This number will increase to an expected number of 642 million by 2040 [ 4 ]. Evidence suggests a strong link between the progression of cognitive impairment, and impaired blood glucose or other metabolic disorders [ 5 , 6 ]. Among the various components of metabolic syndrome, hyperglycemia has the strongest association with the incidence of cognitive impairment[ 7 ]. Type 2 diabetes mellitus (T2DM), in particular, has been associated with a risk of cognitive impairment, including attention disorder, decreased speed of movements, decision-making problems, and incompetent speech memory[ 8 , 9 ]. Diabetes is associated with a 19% increased risk of midlife cognitive decline over 20 years, compared to non-diabetic cases[ 10 ].T2DM, smoking, and obesity are all vascular and non-vascular risk factors for dementia. An analysis of 14 studies involving 2.3 million patients and the incidence of 10,000 cases of dementia in Asia, America, and Europe have shown that diabetes is associated with a 60% increased risk of dementia, with 40% escalated rates of vascular dementia, and the risk increases are about 18% higher in women[ 11 ]. The most common cause of dementia, Alzheimer's disease(AD), is induced by the development of cerebral insulin resistance and impaired glucose regulation in the brain [ 12 , 13 ]. Diabetes patients treated with insulin had four times the risk of dementia than diabetic patients receiving oral therapy or lifestyle modifications. [ 14 ]. The severity of diabetes is also a risk factor in association with elevated risks of dementia. Patients with glucose intolerance have a higher risk of dementia development [ 15 , 16 ]. Moreover, non-diabetics with higher mean glucose levels are also susceptible to dementia [ 17 ]. According to some studies, people with insulin resistance are more likely to develop dementia than people with high plasma glucose levels [ 18 ]. Hence, T2DM progressively increases the overall risk of dementia and AD, especially in uncontrolled cases. According to various studies, precise control of blood glucose in diabetics has been proven to be effective in preventing cognitive impairment, but the exact quantitative association remained unknown. Diabetes-related cognitive impairment is a critical concern for us because it gradually reduces patients' quality of life, resulting in massive health and social care needs. The goal of this study is to determine the prevalence of cognitive impairment and its relationship to diabetes treatments in the diabetic population enrolled in the Bushehr elderly health cohort study. Materials And Methods Sampling and setting This is a cross-sectional approach to data from the phase II Bushehr Elderly Health Program (BEHP). The BEHP is a 3000-participant community-based prospective cohort study in Bushehr, the provincial capital city in southern Iran. The sampling for this study was a multistage stratified random sampling method accomplished in the neighborhoods of Bushehr. The second phase of this study (considering musculoskeletal and cognitive outcomes) started in 2015. In this phase, more than 2400 participants from phase I have enrolled again. The study design and protocol are explained separately (Figure 1). Data gathering The participants were interviewed by competent interviewers to collect data, including sociodemographic factors, types of lifestyles, general health and mental health situations, medical histories, and medicinal uses. Anthropometric measurements were performed through the manual anthropometric procedures of the National Health and Nutrition Examination Survey (NHANES). Weights were measured to 0.1 kg with a Seca leverage bascule with the least wear. Height was measured to the nearest 0.1 centimeters using a fixed stadiometer without shoes and without the head being covered. Waist circumferences were measured at a point midway between the iliac crest and the lowest rib in an upright position after breathing, using a tape in a horizontal plane around the waist, with an accuracy of 0.1 centimeters. Physical activity level (PAL) was assessed by a validated self-report questionnaire defined by different metabolic equivalent (MET) levels ranging from sleep/rest (0.9 METs) to high-intensity physical activities (>6 METs) in 24 hours of sports, work, and leisure time. Over 24 hours, for each activity, MET equivalence was multiplied by the time spent on that particular physical activity. The daily MET was calculated as the sum of MET times. Cognitive function was assessed through two sorts of tools. One of the instruments used was the Mini-Cog, which is a validated tool for cognitive assessment. This test consists of two parts; the first part assesses the ability of participants to recall three different words. Anybody who could recall all of the three words was considered to have normal cognition, and those who could not recall any of the words were considered cognitively impaired. If anyone could only recall one or two words correctly, then a clock drawing test was performed, and if the participant could draw the clock, it was assumed that he or she had a normal cognitive function, and those who could not draw the clock correctly were considered cognitively impaired. The other utilized tool was the categorical verbal fluency test (CFT) which is commonly used for assessing the integrity of semantic memory in individuals with brain damage (ranging from amnesic mild cognitive impairment to dementia). The animal category was used; participants were asked to name as many examples of the category “animal” as possible within one minute. To increase the sensitivity of cognitive impairment diagnosis, participants who were positive in both diagnostic criteria were assumed to be cognitively impaired, and others who were negative in both were considered normal. To determine the values of fasting blood sugar (FBS) and hemoglobin A1C, a blood sample was obtained after overnight fasting. FBS was measured by the enzymatic glucose oxidase method using Pars Azmoon kits that are made in Iran. HbA1c was also measured through the high-performance liquid chromatographic technique. Diabetes was defined based on A1C ≥ 6.5% and FBS ≥ 126 mg/dl or, previous diagnosed history of diabetes. The normal participants were defined based on A1C < 5.7% and FBS < 100 mg/dl. Others beyond the two explained categories were considered pre-diabetics[19] . Ethical consideration The study was approved by the Research Ethics Committee of the Endocrinology & Metabolism Research Institute (Ethical code: IR.TUMS.EMRI.REC.1394.0036). Patient consent forms are obtained from patients, and in the case of confirmation of cognitive impairment (based on the Mini-Cog test), consent forms are obtained from patients' families or legal guardians for study participation. Informed consent was obtained from all study participants. All methods were performed in accordance with the relevant guidelines and regulations. Statistical analysis Concerning statistical analysis, results were presented as mean ± standard deviation (SD) for quantitative variables and were summarized by frequency (percentage) for categorical variables. Continuous variables were compared using a t-test or Mann-Whitney test whenever the data did not appear to have a normal distribution or when the assumption of equal variances was violated across the study groups. Categorical variables, on the other hand, were compared using the chi-square test. The multivariable logistic regression model was utilized to evaluate the association between pre-diabetics and cognitive impairment. For the statistical analysis, the software SPSS version 23.0 for Windows (IBM, Armonk, New York) was used. Results According to the definition of cognitive impairment, pre-diabetes, and diabetes, it was revealed that 693 (45.2%) of the 1533 participants were cognitively impaired, among which 47.3% (328) were normoglycemic, 16.2% (112) were pre-diabetics, and 36.5% (253) were already diagnosed as diabetics ( P <0.001). The characteristics of the total participants and their classifications by normal or impaired cognition are exhibited in table 1. In our study community, cognitive impairment was more prevalent among women (64.8%) compared to men (35.2%) ( P <0 . 001). The means of age, FBS, HbA1c, and LDL cholesterol in cognitively impaired groups were higher compared to normal cognition ( P <0.05); in reverse, the mean of physical activity level was lower in the cognitively impaired group ( P <0.001). Possible related variables which might be related to cognitive function are presented separately among the normoglycemic, pre-diabetic, and diabetic groups in table 2. In all groups, the mean age was higher, and the mean physical activity level was lower in cognitively impaired participants in comparison to normal cognition (P<0.001). Among the cognitively impaired participants, the mean waist circumference was lower only in normoglycemic cases (P = 0.044), the serum LDL-C level was higher only among the diabetic group (P<0.001), and the blood hemoglobin level was lower only among pre-diabetics (P = 0.010). The mean of physical activity based on total weekly MET was slightly lower among cognitively impaired individuals in all three groups (P<0.001). Multivariable analysis was performed to determine the association between the independent predictors such as age, sex, BMI, WC, physical activity, smoking history, FBS, triglyceride, and LDL with cognitive impairment in the three normoglycemic, pre-diabetic, and diabetic groups. Odds ratios for age differences were calculated at 1.12, 1.06, and 1.09 in normoglycemic, pre-diabetic, and diabetic participants, respectively, which indicates that the cognitively impaired patients were older in all three groups (p<0.001). Women were more likely to have cognitive impairment in all three groups (OR = 0.21; CI 95% 0.15– 0.30 P 0.001, OR = 0.33; CI 95% 0.19–0.59 P 0.001, OR = 0.33; CI 95% 0.22-0.50 P 0.001).The association between physical activity level and smoking with cognitive impairment was only significant in diabetic patients (OR = 0.94; CI 95% 0.90-0.99, P = 0.018) and normoglycemic participants (OR = 1.32; CI 95% 1.07-1.62, P = 0.007), respectively (Table 3).In logistic regression models, the association between prediabetes and diabetes with cognitive impairment demarcated by gender was assessed. In univariate models, only diabetes (but not pre-diabetes) was associated with cognitive impairment (OR = 1.54; CI 95% 1.22-1.93, P<0.001). This association was sustained in multivariate models after adjustment for associated confounders, including age, sex, BMI, WC, physical activity, serum hemoglobin A1C, and smoking (Table 4). Participants (44.9%) were cognitively impaired (64.5% female and 31.0% male, P< 0.001). Discussion The purpose of this study was to thoroughly assess cognitive disorders in diabetic elderly people. We concluded in our study population that diabetic patients were more vulnerable to cognitive impairment and that lower physical activity would increase the chances of diabetic patients living with cognitive impairment. It was discovered that hyperglycemia in diabetic patients predisposes them to cognitive impairment the most, and after adjustment of underlying factors such as age, gender, BMI, waist circumference, physical activity, and smoking, we estimated that the incidence of cognitive impairment in diabetic patients increases up to 1.48 times. Furthermore, characteristics such as advanced age, female gender, a positive history of hypertension, widowhood, elevated LDL-C, and even low MET energy expenditure can all be considered risk factors for cognitive impairment. Overall, given diabetics' susceptibility to cognitive impairment, it is reasonable to expect that better glycemic control can suspend the progression of cognitive impairment or even reverse it. Our study's findings were consistent with those of previous studies. According to the study by Xue et al. [ 20 ], diabetes increased the risk of cognitive impairment by 1.25 to 1.91 times, also fasting glucose levels, HbA1C levels, and insulin resistance index had a significant linear relationship with the incidence and progression of dementia. A study by Gao et al. [ 21 ] propounded the duration from onset of diabetes as a risk factor for dementia among the diabetic population alongside other risk factors like higher levels of age, current smoking, mean waist circumference, duration of diabetes, insulin intake, systolic blood pressure, FBS, HgA1c, and, immunoreactive insulin (IRI). According to Tiwari et al. [ 22 ], cognitive impairment is expected to be 1.3 times more common in diabetics. As reported by Sun et al.[ 23 ] age, education level, diabetes duration, FBS, and A1C levels all contribute to cognitive impairment in older T2DM. Another study by Jia et al.[ 24 ] in China considered old age, female gender, low levels of education, widowhood or divorce, smoking history, hypertension, cardiovascular diseases, and ischemic brain diseases as the risk factors for dementia among patients with diabetes. They also illustrated that the prevalence of cognitive impairment increased in diabetics 2.14 times. Consequently, T2DM, especially in poorly controlled conditions, predisposes to disparate stages of cognitive impairment, and some of the conditions associated with diabetes seem to exacerbate that impairment [ 24 ]. Several studies have been conducted about the pathophysiology and progression of cognitive impairment. Impaired insulin signaling and insulin receptor sensitivity in neurons and dendritic branches in Alzheimer‘s patients indicate a link between diabetes and cognitive impairment [ 25 ]. The second related consequence is mitochondrial dysfunction. Insulin is essential for increasing mitochondrial activity in hippocampal synaptosomes [ 26 ]. Cerebral mitochondrial function declines in AD patients, which has been linked to cortical hypometabolism and impaired insulin signaling in the brain. In this regard, the pattern of metabolic changes in AD patients has influenced mitochondrial bioenergetic inhibitors [ 27 ]. Hence, mitochondrial functions after the metabolic regulations are affected by insulin, manipulating cognitive functions [ 28 ]. The relationship between diabetic autonomic neuropathy and the incidence of cognitive impairment is a further considerable issue. It has been demonstrated that diabetic autonomic neuropathy is related intimately to hypertension and increased risk of cerebral stroke, both of which are associated with cognitive impairment. Neuroinflammation and brain changes are two other significant concerns raised regarding diabetic cognitive impairment. Accumulation of inflammatory cytokines in the brain has been confirmed in diabetics, which has a significant effect on neuronal damage [ 29 ]. Moreover, NF-kb regulates oxygen radicals and the expression of TNF and variegated interleukins and therefore has an unassailable influence on initiating and activating the inflammatory cascade. High TNF levels and activity inhibit the insulin signaling pathway, which leads to increased production of oxygen radicals or ROS and the progression of cognitive impairment in these individuals [ 30 – 32 ]. According to Sundermann's findings, even prediabetes harms brain metabolism in older men and women. In light of previous findings linking T2DM to reduced brain volume and AD pathology[ 33 – 37 ], the findings of this study suggest that functional changes may occur before brain volume changes in the early stages of T2DM[ 38 ]. This study also revealed that prediabetes was associated with poorer executive function overall and language performance specifically in the context of mean cognitive impairment (MCI) in women only[ 38 ]. Despite this fact that even though these findings and the sex distribution contradict our findings. Dybjer et. al[ 39 ]. discovered that pre-diabetes and newly diagnosed diabetes are linked to MCI, and that blood glucose levels, even at the upper end of the normal range, may have a marginally negative effect on cognition. As compared to a healthy individual with normal glucose tolerance, prediabetes or diabetes had slight negative effects on memory, processing speed, and executive functioning[ 39 ]. Since there is no association between prediabetics and cognitive impairment, our findings contradict this article. This could be due to different thresholds for diagnosing prediabetic patients, sample size randomization, or the cognitive impairment assessment system. This should be investigated further in future studies on the matter. Conclusion In conclusion, we discovered that T2DM, particularly in persistent uncontrolled conditions, has a positive association with cognitive impairment in the elderly population. Aside from diabetes' inflammatory effect on the progression of cognitive disorders, we propose that old age, female gender, history of hypertension, widowhood, increased LDL-C, and even low-calorie consumption are additional risk factors for cognitive impairment. It is also worth noting that in our study, there was no association between prediabetic patients and cognitive impairment. Declarations Ethics approval and consent to participate: The study was approved by the Research Ethics Committee of the Endocrinology & Metabolism Research Institute (Ethical code: IR.TUMS.EMRI.REC.1394.0036). Patient consent forms are obtained from patients, and in the case of confirmation of cognitive impairment (based on the Mini-Cog test), consent forms are obtained from patients' families or legal guardians for study participation. Informed consent was obtained from all study participants. All methods were performed in accordance with the relevant guidelines and regulations. Consent for publication: Not Applicable Availability of data and materials: The datasets used and/or analysed during the current study available from the corresponding author on reasonable request. Acknowledgements: Implementation of this study was sponsored by Tehran University of Medical Sciences (Endocrinology and Metabolism Research Institute). Competing interest: All authors declare that they have no conflict of interest. Fundings: None Author Contributions Statement: SF,ME,AO,MP,FSH,YSH,SM and ZSH in the study design, writing of the paper, and had significant role in analyzing data. BL participated in critical review. All authors read, provided feedback, and approved the final paper. References Pal K, Mukadam N, Petersen I, Cooper C: Mild cognitive impairment and progression to dementia in people with diabetes , prediabetes and metabolic syndrome : a systematic review and meta - analysis . Social psychiatry and psychiatric epidemiology 2018, 53 (11):1149–1160. Moran C, Callisaya ML, Srikanth V, Arvanitakis Z: Diabetes therapies for dementia . Current neurology and neuroscience reports 2019, 19 (8):1–9. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP: The global prevalence of dementia : a systematic review and metaanalysis . Alzheimer's & dementia 2013, 9 (1):63–75. e62. Ogurtsova K: dRF J. , Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al . IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015:40–50. Wong RHX, Scholey A, Howe PRC: Assessing premorbid cognitive ability in adults with type 2 diabetes mellitus—a review with implications for future intervention studies . Current diabetes reports 2014, 14 (11):547. Grünblatt E, Bartl J, Riederer P: The link between iron, metabolic syndrome, and Alzheimer’s disease . Journal of Neural Transmission 2011, 118 (3):371–379. Dik MG, Jonker C, Comijs HC, Deeg DJ, Kok A, Yaffe K, Penninx BW: Contribution of metabolic syndrome components to cognition in older individuals . Diabetes care 2007, 30 (10):2655–2660. Palta P, Schneider AL, Biessels GJ, Touradji P, Hill-Briggs F: Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains . Journal of the International Neuropsychological Society 2014, 20 (3):278–291. Monette MC, Baird A, Jackson DL: A meta-analysis of cognitive functioning in nondemented adults with type 2 diabetes mellitus . Canadian journal of diabetes 2014, 38 (6):401–408. Rawlings AM, Sharrett AR, Schneider AL, Coresh J, Albert M, Couper D, Griswold M, Gottesman RF, Wagenknecht LE, Windham BG: Diabetes in midlife and cognitive change over 20 years: a cohort study . Annals of internal medicine 2014, 161 (11):785–793. Chatterjee S, Peters SA, Woodward M, Mejia Arango S, Batty GD, Beckett N, Beiser A, Borenstein AR, Crane PK, Haan M et al : Type 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia . Diabetes Care 2016, 39 (2):300–307. de la Monte SM: Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease . Curr Alzheimer Res 2012, 9 (1):35–66. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB: Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 2011, 71 (3):365–376. Ott A, Stolk RP, van Harskamp F, Pols HAP, Hofman A, Breteler MMB: Diabetes mellitus and the risk of dementia . Neurology 1999, 53 (9):1937. N S, Karan: Assessment of the cognitive status in diabetes mellitus . J Clin Diagn Res 2012, 6 (10):1658–1662. Luchsinger JA: Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective . Eur J Pharmacol 2008, 585 (1):119–129. Crane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H, Haneuse S, Craft S, Montine TJ, Kahn SE et al : Glucose levels and risk of dementia . N Engl J Med 2013, 369 (6):540–548. Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, Kanba S, Kiyohara Y: Glucose tolerance status and risk of dementia in the community: the Hisayama study . Neurology 2011, 77 (12):1126–1134. Ika K, Suzuki E, Mitsuhashi T, Takao S, Doi H: Shift work and diabetes mellitus among male workers in Japan: does the intensity of shift work matter? Acta Med Okayama 2013, 67 (1):25–33. Xue M, Xu W, Ou YN, Cao XP, Tan MS, Tan L, Yu JT: Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies . Ageing Res Rev 2019, 55 :100944. Gao Y, Xiao Y, Miao R, Zhao J, Cui M, Huang G, Fei M: The prevalence of mild cognitive impairment with type 2 diabetes mellitus among elderly people in China: A cross-sectional study . Arch Gerontol Geriatr 2016, 62 :138–142. Tiwari SC, Tripathi RK, Farooqi SA, Kumar R, Srivastava G, Kumar A: Diabetes mellitus: A risk factor for cognitive impairment amongst urban older adults . Ind Psychiatry J 2012, 21 (1):44–48. Sun L, Diao X, Gang X, Lv Y, Zhao X, Yang S, Gao Y, Wang G: Risk Factors for Cognitive Impairment in Patients with Type 2 Diabetes . J Diabetes Res 2020, 2020 :4591938. Jia HH, Liu L, Huo GX, Wang RQ, Zhou YQ, Yang LY: A qualitative study of the cognitive behavioral intention of patients with diabetes in rural China who have experienced delayed diagnosis and treatment . BMC Public Health 2020, 20 (1):478. Calvo-Ochoa E, Arias C: Cellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal models . Diabetes Metab Res Rev 2015, 31 (1):1–13. Heras-Sandoval D, Ferrera P, Arias C: Amyloid-β protein modulates insulin signaling in presynaptic terminals . Neurochemical research 2012, 37 (9):1879–1885. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW: Identification of oxidized plasma proteins in Alzheimer's disease . Biochemical and biophysical research communications 2002, 293 (5):1566–1570. Lu T, Pan Y, Kao S, Li C, Kohane I: chan , J.; Yankner, BA . Nature 2004, 429 :883. Gaspar JM, Baptista FI, Macedo MP, Ambrosio AF: Inside the diabetic brain: role of different players involved in cognitive decline . ACS Chemical Neuroscience 2016, 7 (2):131–142. Wang J, Li G, Wang Z, Zhang X, Yao L, Wang F, Liu S, Yin J, Ling E-A, Wang L: High glucose-induced expression of inflammatory cytokines and reactive oxygen species in cultured astrocytes . Neuroscience 2012, 202 :58–68. Sima AA: Encephalopathies: the emerging diabetic complications . Acta diabetologica 2010, 47 (4):279–293. Kuhad A, Bishnoi M, Tiwari V, Chopra K: Suppression of NF-κβ signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits . Pharmacology Biochemistry and Behavior 2009, 92 (2):251–259. Moran C, Phan TG, Chen J, Blizzard L, Beare R, Venn A, Münch G, Wood AG, Forbes J, Greenaway TM: Brain atrophy in type 2 diabetes: regional distribution and influence on cognition . Diabetes care 2013, 36 (12):4036–4042. Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V: Type 2 diabetes mellitus and biomarkers of neurodegeneration . Neurology 2015, 85 (13):1123–1130. Biessels GJ, Reijmer YD: Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI? Diabetes 2014, 63 (7):2244–2252. Callisaya ML, Beare R, Moran C, Phan T, Wang W, Srikanth VK: Type 2 diabetes mellitus, brain atrophy and cognitive decline in older people: a longitudinal study . Diabetologia 2019, 62 (3):448–458. Bangen KJ, Werhane ML, Weigand AJ, Edmonds EC, Delano-Wood L, Thomas KR, Nation DA, Evangelista ND, Clark AL, Liu TT: Reduced regional cerebral blood flow relates to poorer cognition in older adults with type 2 diabetes . Frontiers in aging neuroscience 2018:270. Sundermann EE, Thomas KR, Bangen KJ, Weigand AJ, Eppig JS, Edmonds EC, Wong CG, Bondi MW, Delano-Wood L: Prediabetes Is Associated With Brain Hypometabolism and Cognitive Decline in a Sex-Dependent Manner: A Longitudinal Study of Nondemented Older Adults . Frontiers in Neurology 2021, 12 . Dybjer E, Nilsson PM, Engström G, Helmer C, Nägga K: Pre-diabetes and diabetes are independently associated with adverse cognitive test results: a cross-sectional, population-based study . BMC endocrine disorders 2018, 18 (1):1–10. Tables Table 1- Characteristics of the participants Total Participants N=1533 normal cognition N = 840 Impaired cognition N = 693 P-value Age, year 69.2±6.5 67.6±5.2 71.2±7.3 <0.001 Sex, % female male 750 (48.9) 783 (51.1) 301 (35.8) 539 (64.2) 449 (64.8) 244 (35.2) <0.001 BMI, kg/m 2 30.9±5.1 WC, cm 98.5±11.9 98.5±11.2 98.4±12.8 0.917 Education, % Illiterate Primary School High School Diploma Academic 563 (36.7) 540 (35.2) 136 (8.9) 196 (12.8) 98 (6.4) 320 (38.1) 278 (33.1) 82 (9.8) 102 (12.1) 58 (6.9) 243 (35.1) 262 (37.8) 54 (7.8) 94 (13.6) 40 (5.8) 0.173 Marital status, % Single Married Divorced Widow- Widower 13 (0.8) 1195 (77.9) 13 (0.8) 312 (20.4) 6 (0.7) 731 (87.0) 7 (0.8) 96 (11.4) 7 (1.0) 464 (67.0) 6 (0.9) 216 (31.2) <0.001 Smoking, % Occasionally smoker Current smoker 66 (4.3) 256 (16.7) 30 (3.6) 132 (15.7) 36 (5.2) 124 (17.9) 0.132 Glycemia, % Normo-glycemia Prediabetes Diabetes 792 (51.7) 256 (16.7) 485 (31.6) 464 (55.2) 144 (17.1) 232 (27.6) 328 (47.3) 112 (16.2) 253 (36.5) 0.001 Hypertension, % 1084 (70.7) 573 (68.2) 511 (73.7) 0.018 HbA1c, % 5.6±1.5 5.5±1.4 5.8±1.6 0.004 normal glycemia 4.7±0 .5 4.8±0 .4 4.7±0 .5 0.241 Prediabetes 5.6±0 .7 5.5±0 .7 5.6±0 .6 0.148 Diabetes 7.1± 1.8 7.1± 1.7 7.2± 1.9 0.754 FBS 105.0±41.2 102.1±35.0 108.7±47.4 0.002 normal glycemia 85.7±7.8 86.1±7.6 85.0±8.1 0.054 Prediabetes 101.0±14.0 101.3±14.2 100.6±13.8 0.672 Diabetes 138.9±58.2 134.5±51.5 143.1±63.6 0.103 Triglyceride, mg/dl 133.8±67.3 133.6±69.9 134.1±63.9 0.871 LDL, mg/dl 109.1±37.5 107.2±37.5 111.5±37.5 0.028 HDL, mg/dl 45.7±11.0 45.5±11.2 45.9±10.7 0.522 Total weekly MET (kcal/kg/day) 30.9±5.1 31.7±5.1 29.9±4.8 <0.001 WC: waist circumference; HbA1c: hemoglobin A1c; FBS: fasting blood sugar; LDL: low-density lipoprotein; HDL: high-density lipoprotein Table 2- Characteristics of the participants Variable Normo-glycemia Pre-diabetes Diabetes normal C N = 464 CI N = 328 P-value normal C N = 144 CI N = 112 P value normal C N = 232 CI N = 253 P value Age, year 67.5±5.0 71.9±7.8 <0.001 68.6±6.4 72.2±7.3 <0.001 67.1±4.5 69.8± 6.4 <0.001 WC/cm 96.9±11.2 95.2±12.8 0.044 100.0±10.3 100.0±13.5 0.979 100.6±11.0 101.9±11.4 0.218 HbA1c, % 4.8±0 .4 4.7±0 .5 0.241 5.5±0 .7 5.6±0 .6 0.148 7.1± 1.7 7.2± 1.9 0.754 FBS, mg/dl 86.1±7.6 85.0±8.1 0.054 101.3±14.2 100.6±13.8 0.672 134.5±51.5 143.1±63.6 0.103 Triglyceride, mg/dl 125.8±61.0 118.3±52.1 0.072 143.6±76.4 152.0±80.6 0.391 142.8±80.1 146.7±64.9 0.559 LDL, mg/dl 114.4±34.6 116.0±35.7 0.524 111.3±44.5 118.8±38.3 0.158 90.3±32.7 102.3±37.9 <0.001 HDL, mg/dl 46.2±11.1 47.2±11.1 0.198 45.1±11.0 46.3±10.0 0.346 44.3± 11.3 43.8±10.1 0.618 Hemoglobin, g/dl 14.6±1.5 14.5± 1.8 0.121 14.7±1.8 14.1±2.0 0.010 14.2±1.7 14.2±1.7 0.785 Total weekly MET (kcal/kg/day) 31.9±5.1 30.3±5.1 <0.001 31.5±5.2 29.2±4.4 <0.001 31.3±4.9 29.5±4.5 <0.001 WC: waist circumference; HbA1c: hemoglobin A1c; FBS: fasting blood sugar; LDL: low-density lipoprotein; HDL: high-density lipoprotein Table 3- Associations of possibly related variables with cognitive impairment Variable Normal (n=780) Pre-diabetes (n=245) Diabetes (n=480) OR 95% CI OR P -value OR 95% CI OR P -value OR 95% CI OR P -value Age 1.12 1.09- 1.15 <0.001 1.06 1.01-1.11 0.007 1.09 1.05-1.13 <0.001 Sex 0.21 0.15- 0.30 <0.001 0.33 0.19-0.59 <0.001 0.33 0.22-0.50 <0.001 BMI 0.63 0.29- 1.36 0.248 2.15 0.58-7.89 0.248 2.39 0.83-6.81 0.103 WC 0.99 0.98-1.00 0.385 1.00 0.98-1.03 0.646 1.01 0.99-1.02 0.261 Physical activity 0.98 0.95-1.01 0.377 0.93 0.87-1.00 0.070 0.94 0.90-0.99 0.018 Smoking 1.32 1.07-1.62 0.007 0.78 0.53-1.17 0.245 1.25 0.93-1.68 0.135 FBS 0.99 0.97-1.01 0.396 1.00 0.98-1.02 0.749 1.00 1.00-1.01 0.050 Triglyceride 0.99 0.99-1.00 0.138 1.00 0.99-1.00 0.090 0.99 0.99-1.00 0.662 LDL 0.99 0.99-1.00 0.430 1.00 0.99-1.01 0.319 1.00 1.00-1.01 0.006 BMI: body mass index; WC: waist circumference; FBS: fasting blood sugar; LDL: low-density lipoprotein; Table 4- Associations of pre-diabetes and diabetes with cognitive impairment OR 95% CI OR P -value Unadjusted model Pre-diabetes 1.10 0.82-1.46 0.510 Diabetes 1.54 1.22-1.93 <0.001 Adjusted models Pre-diabetes 1 0.99 0.74-1.34 0.999 Diabetes 1.37 1.08-1.73 0.009 Pre-diabetes 2 0.91 0.66- 1.24 0.554 Diabetes 1.51 1.18- 1.94 0.001 Pre-diabetes 3 0.96 0.70-1.32 0.826 Diabetes 1.59 1.24-2.05 0.000 Pre-diabetes 4 0.92 0.67-1.27 0.637 Diabetes 1.46 1.12-1.88 0.004 Pre-diabetes 5 0.92 0.66-1.27 0.612 Diabetes 1.50 1.16-1.94 0.002 Pre-diabetes 6 0.91 0.66-1.26 0.603 Diabetes 1.51 1.16-1.96 0.002 Pre-diabetes 7 0.92 0.67-1.27 0.630 Diabetes 1.48 1.14-1.91 0.003 OR: Odds Ratio, CI: Confidence Interval 1 Adjusted for age, sex 2 Adjusted for age, sex 3 Adjusted for age, sex, BMI 4 Adjusted for age, sex, BMI, WC, physical activity 5 Adjusted for age, sex, BMI, WC, physical activity, serum hemoglobin 6 Adjusted for age, sex, BMI, WC, physical activity, serum hemoglobin, and smoking 7 Adjusted for age, sex, BMI, WC, physical activity, smoking Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 18 Oct, 2023 Read the published version in Journal of Diabetes & Metabolic Disorders → Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1658783","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":109687786,"identity":"41bed0e5-3419-4d8b-8198-e4b481719ad1","order_by":0,"name":"Sara Farkhani","email":"","orcid":"","institution":"Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Sara","middleName":"","lastName":"Farkhani","suffix":""},{"id":109687788,"identity":"64c40e3d-7742-497b-a971-47bdcc27bb5e","order_by":1,"name":"Moloud Payab","email":"","orcid":"","institution":"Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Moloud","middleName":"","lastName":"Payab","suffix":""},{"id":109687789,"identity":"0effe001-c0db-4bf3-80a9-7ad542643bdd","order_by":2,"name":"Farshad Sharifi","email":"","orcid":"","institution":"Elderly Health Research Center,Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Farshad","middleName":"","lastName":"Sharifi","suffix":""},{"id":109687790,"identity":"c82bddd5-c331-4996-af0c-9568f24f447d","order_by":3,"name":"Yasaman Sharifi","email":"","orcid":"","institution":"Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Yasaman","middleName":"","lastName":"Sharifi","suffix":""},{"id":109687791,"identity":"6f049398-e207-4ed1-bbc4-acd1d41e4a11","order_by":4,"name":"Sammy Mohammadi","email":"","orcid":"","institution":"Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Sammy","middleName":"","lastName":"Mohammadi","suffix":""},{"id":109687792,"identity":"c88a259b-1cb0-4f7c-86bc-d43ede626366","order_by":5,"name":"Zhaleh Shadman","email":"","orcid":"","institution":"Elderly Health Research Center,Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Zhaleh","middleName":"","lastName":"Shadman","suffix":""},{"id":109687793,"identity":"02bc6f92-a809-47db-9a3a-3841b5e74a4f","order_by":6,"name":"Noushin Fahimfar","email":"","orcid":"","institution":"Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Noushin","middleName":"","lastName":"Fahimfar","suffix":""},{"id":109687794,"identity":"506176cb-63a9-40e0-9dc3-60759092c498","order_by":7,"name":"Ramin Heshmat","email":"","orcid":"","institution":"Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Ramin","middleName":"","lastName":"Heshmat","suffix":""},{"id":109687795,"identity":"f7279db7-6f9f-4a44-ae74-c2f12f7bec48","order_by":8,"name":"Alireza Hadizadeh","email":"","orcid":"","institution":"Research Center for Advanced Technologies in Cardiovascular Medicine, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Alireza","middleName":"","lastName":"Hadizadeh","suffix":""},{"id":109687796,"identity":"dee2de2c-ec06-4724-9e24-66e87aba51f7","order_by":9,"name":"Gita Shafiee","email":"","orcid":"","institution":"Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Gita","middleName":"","lastName":"Shafiee","suffix":""},{"id":109687797,"identity":"5cff9095-edcb-4090-9921-0d8c670f9c7a","order_by":10,"name":"Iraj Nabipour","email":"","orcid":"","institution":"The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Iraj","middleName":"","lastName":"Nabipour","suffix":""},{"id":109687798,"identity":"cefcec22-68f0-4f3f-9abd-c92a8293d38b","order_by":11,"name":"Bagher Larijani","email":"","orcid":"","institution":"Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Bagher","middleName":"","lastName":"Larijani","suffix":""},{"id":109687799,"identity":"0528308b-62c4-4e54-abae-73061283e30e","order_by":12,"name":"mahbube ebrahimpur","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA5UlEQVRIiWNgGAWjYHACNiA+wANmfoALGhCphXFGAglawCxmngR8CqFAt4H52OOKmjsyurN7zD7b/jgcLd/A/PADQ8E9nFrMDrClG5459ozH7M4Z49k5CYdzNxxgM5ZgMCjGreX+GzPJBrbDPGY3coyZwVqAgkC/4Hai2QH+b5IN/6BaLIBa5jewfyOghYdNsrENqoUBqKXhAA8hW9jMDRv7gFruHCtm7ElLz91wmKdYIgGvFuZnDxu+HbY3u928meGHjXXu/Pb2jR8+/MGtBQEkYAxmICZGA5KWUTAKRsEoGAVoAAA9BVKIbctuQgAAAABJRU5ErkJggg==","orcid":"","institution":"Elderly Health Research Center,Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"mahbube","middleName":"","lastName":"ebrahimpur","suffix":""},{"id":109687800,"identity":"5ed46da1-4def-43ad-a78d-1059db9c5a7b","order_by":13,"name":"Afshin ostovar","email":"","orcid":"","institution":"Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Afshin","middleName":"","lastName":"ostovar","suffix":""}],"badges":[],"createdAt":"2022-05-15 15:59:04","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1658783/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1658783/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s40200-023-01325-y","type":"published","date":"2023-10-18T11:30:29+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":22318430,"identity":"7dfc244e-3764-46ea-9aa8-2f4f05d57c76","added_by":"auto","created_at":"2022-06-06 18:26:17","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":17543,"visible":true,"origin":"","legend":"\u003cp\u003eFlow chart of enrolments in this study\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-1658783/v1/b3701db73e23d7fd6b3b718f.png"},{"id":58941776,"identity":"fbb2c9ef-e4b1-49bc-a2c5-94498ddfeccd","added_by":"auto","created_at":"2024-06-24 11:30:34","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1579816,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1658783/v1/e759b162-97f9-4159-be9c-1a88e9051f2f.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Association between pre-diabetes or diabetes and cognitive impairment in a -community dwelling older population: Bushehr Elderly Health (BEH) program","fulltext":[{"header":"Introduction","content":"\u003cp\u003eDiabetes and cognitive disorders have become more prevalent in the last decade as a result of lifestyle and demographic changes[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. Dementia is a clinical syndrome characterized by progressive declines in cognitive and functional ability [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. It is estimated that approximately 50\u0026nbsp;million people worldwide suffer from dementia, with the figure expected to nearly double every 20 years to approximately 115\u0026nbsp;million by 2050.[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. According to the 2015 diabetes prevalence figures, approximately 415\u0026nbsp;million people worldwide suffer from diabetes. This number will increase to an expected number of 642\u0026nbsp;million by 2040 [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e]. Evidence suggests a strong link between the progression of cognitive impairment, and impaired blood glucose or other metabolic disorders [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e, \u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Among the various components of metabolic syndrome, hyperglycemia has the strongest association with the incidence of cognitive impairment[\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. Type 2 diabetes mellitus (T2DM), in particular, has been associated with a risk of cognitive impairment, including attention disorder, decreased speed of movements, decision-making problems, and incompetent speech memory[\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Diabetes is associated with a 19% increased risk of midlife cognitive decline over 20 years, compared to non-diabetic cases[\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e].T2DM, smoking, and obesity are all vascular and non-vascular risk factors for dementia. An analysis of 14 studies involving 2.3\u0026nbsp;million patients and the incidence of 10,000 cases of dementia in Asia, America, and Europe have shown that diabetes is associated with a 60% increased risk of dementia, with 40% escalated rates of vascular dementia, and the risk increases are about 18% higher in women[\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. The most common cause of dementia, Alzheimer's disease(AD), is induced by the development of cerebral insulin resistance and impaired glucose regulation in the brain [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]. Diabetes patients treated with insulin had four times the risk of dementia than diabetic patients receiving oral therapy or lifestyle modifications. [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. The severity of diabetes is also a risk factor in association with elevated risks of dementia. Patients with glucose intolerance have a higher risk of dementia development [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e, \u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e]. Moreover, non-diabetics with higher mean glucose levels are also susceptible to dementia [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]. According to some studies, people with insulin resistance are more likely to develop dementia than people with high plasma glucose levels [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. Hence, T2DM progressively increases the overall risk of dementia and AD, especially in uncontrolled cases. According to various studies, precise control of blood glucose in diabetics has been proven to be effective in preventing cognitive impairment, but the exact quantitative association remained unknown. Diabetes-related cognitive impairment is a critical concern for us because it gradually reduces patients' quality of life, resulting in massive health and social care needs. The goal of this study is to determine the prevalence of cognitive impairment and its relationship to diabetes treatments in the diabetic population enrolled in the Bushehr elderly health cohort study.\u003c/p\u003e"},{"header":"Materials And Methods","content":"\u003cp\u003e\u003cstrong\u003eSampling and setting\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis is a cross-sectional approach to data from the phase II Bushehr Elderly Health Program (BEHP). The BEHP is a 3000-participant community-based prospective cohort study in Bushehr, the provincial capital city in southern Iran. The sampling for this study was a multistage stratified random sampling method accomplished in the neighborhoods of Bushehr. The second phase of this study (considering musculoskeletal and cognitive outcomes) started in 2015. In this phase, more than 2400 participants from phase I have enrolled again. The study design and protocol are explained separately (Figure 1).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData gathering\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe participants were interviewed by competent interviewers to collect data, including sociodemographic factors, types of lifestyles, general health and mental health situations, medical histories, and medicinal uses. Anthropometric measurements were performed through the manual anthropometric procedures of the National Health and Nutrition Examination Survey (NHANES).\u0026nbsp;Weights were measured to 0.1 kg with a Seca leverage bascule with the least wear. Height was measured to the nearest 0.1 centimeters using a fixed stadiometer without shoes and without the head being covered. Waist circumferences were measured at a point midway between the iliac crest and the lowest rib in an upright position after breathing, using a tape in a horizontal plane around the waist, with an accuracy of 0.1 centimeters. Physical activity level (PAL) was assessed by a validated self-report questionnaire defined by different metabolic equivalent (MET) levels ranging from sleep/rest (0.9 METs) to high-intensity physical activities (\u0026gt;6 METs) in 24 hours of sports, work, and leisure time. Over 24 hours, for each activity, MET equivalence was multiplied by the time spent on that particular physical activity. The daily MET was calculated as the sum of MET times. Cognitive function was assessed through two sorts of tools. One of the instruments used was the Mini-Cog, which is a validated tool for cognitive assessment. This test consists of two parts; the first part assesses the ability of participants to recall three different words. Anybody who could recall all of the three words was considered to have normal cognition, and those who could not recall any of the words were considered cognitively impaired. If anyone could only recall one or two words correctly, then a clock drawing test was performed, and if the participant could draw the clock, it was assumed that he or she had a normal cognitive function, and those who could not draw the clock correctly were considered cognitively impaired. The other utilized tool was the categorical verbal fluency test (CFT) which is commonly used for assessing the integrity of semantic memory in individuals with brain damage (ranging from amnesic mild cognitive impairment to dementia). The animal category was used; participants were asked to name as many examples of the category \u0026ldquo;animal\u0026rdquo; as possible within one minute. To increase the sensitivity of cognitive impairment diagnosis, participants who were positive in both diagnostic criteria were assumed to be cognitively impaired, and others who were negative in both were considered normal. To determine the values of fasting blood sugar (FBS) and hemoglobin A1C, a blood sample was obtained after overnight fasting. FBS was measured by the enzymatic glucose oxidase method using Pars Azmoon kits that are made in Iran. HbA1c was also measured through the high-performance liquid chromatographic technique. Diabetes was defined based on A1C\u0026nbsp;\u0026ge;\u0026nbsp;6.5%\u003cspan dir=\"RTL\"\u003e\u0026nbsp;\u003c/span\u003eand FBS\u0026nbsp;\u0026ge;\u0026nbsp;126 mg/dl or, previous diagnosed history of diabetes. The normal participants were defined based on A1C \u0026lt; 5.7% and FBS \u0026lt; 100 mg/dl. Others beyond the two explained categories were considered pre-diabetics[19]\u003csup\u003e.\u003c/sup\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthical consideration\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study was approved by the Research Ethics Committee of the Endocrinology \u0026amp; Metabolism Research Institute (Ethical code: IR.TUMS.EMRI.REC.1394.0036). Patient consent forms are obtained from patients, and in the case of confirmation of cognitive impairment (based on the Mini-Cog test), consent forms are obtained from patients\u0026apos; families or legal guardians for study participation. Informed consent was obtained from all study participants. \u0026nbsp;All methods were performed in accordance with the relevant guidelines and regulations.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConcerning statistical analysis, results were presented as mean \u0026plusmn; standard deviation (SD) for quantitative variables and were summarized by frequency (percentage) for categorical variables. Continuous variables were compared using a t-test or Mann-Whitney test whenever the data did not appear to have a normal distribution or when the assumption of equal variances was violated across the study groups. Categorical variables, on the other hand, were compared using the chi-square test. The multivariable logistic regression model was utilized to evaluate the association between pre-diabetics and cognitive impairment. For the statistical analysis, the software SPSS version 23.0 for Windows (IBM, Armonk, New York) was used. \u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eAccording to the definition of cognitive impairment, pre-diabetes, and diabetes, it was revealed that 693 (45.2%) of the 1533 participants were cognitively impaired, among which 47.3% (328) were normoglycemic, 16.2% (112) were pre-diabetics, and 36.5% (253) were already diagnosed as diabetics (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.001).\u0026nbsp; The characteristics of the total participants and their classifications by normal or impaired cognition are exhibited in table 1. In our study community, cognitive impairment was more prevalent among women (64.8%) compared to men (35.2%) (\u003cem\u003eP\u003c/em\u003e\u0026lt;0\u003cem\u003e.\u003c/em\u003e001).\u0026nbsp;The means of age, FBS, HbA1c, and LDL cholesterol in cognitively impaired groups were higher compared to normal cognition\u0026nbsp;(\u003cem\u003eP\u003c/em\u003e\u0026lt;0.05); in reverse, the mean of physical activity level was lower in the cognitively impaired group (\u003cem\u003eP\u003c/em\u003e\u0026lt;0.001).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ePossible related variables which might be related to cognitive function are presented separately among the normoglycemic, pre-diabetic, and diabetic groups in table 2. In all groups, the mean age was higher, and the mean physical activity level was lower in cognitively impaired participants in comparison to normal cognition (P\u0026lt;0.001). Among the cognitively impaired participants, the mean waist circumference was lower only in normoglycemic cases (P = 0.044), the serum LDL-C level was higher only among the diabetic group (P\u0026lt;0.001), and the blood hemoglobin level was lower only among pre-diabetics (P = 0.010). The mean of physical activity based on total weekly MET was slightly lower among cognitively impaired individuals in all three groups (P\u0026lt;0.001).\u003cspan dir=\"RTL\"\u003e\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n\u003cp\u003eMultivariable analysis was performed to determine the association between the independent predictors such as age, sex, BMI, WC, physical activity, smoking history, FBS, triglyceride, and LDL with cognitive impairment in the three normoglycemic, pre-diabetic, and diabetic groups. Odds ratios for age differences were calculated at 1.12, 1.06, and 1.09 in normoglycemic, pre-diabetic, and diabetic participants, respectively, which indicates that the cognitively impaired patients were older in all three groups (p\u0026lt;0.001). Women were more likely to have cognitive impairment in all three groups (OR = 0.21; CI 95% 0.15\u0026ndash; 0.30 P 0.001, OR = 0.33; CI 95% 0.19\u0026ndash;0.59 P 0.001, OR = 0.33; CI 95% 0.22-0.50 P 0.001).The association between physical activity level and smoking with cognitive impairment was only significant in diabetic patients (OR = 0.94; CI 95% 0.90-0.99, P = 0.018) and normoglycemic participants (OR = 1.32; CI 95% 1.07-1.62, P = 0.007), respectively (Table 3).In logistic regression models, the association between prediabetes and diabetes with cognitive impairment demarcated by gender was assessed. In univariate models, only diabetes (but not pre-diabetes) was associated with cognitive impairment (OR = 1.54; CI 95% 1.22-1.93, P\u0026lt;0.001). This association was sustained in multivariate models after adjustment for associated confounders, including age, sex, BMI, WC, physical activity, serum hemoglobin A1C, and smoking (Table 4). Participants (44.9%) were cognitively impaired (64.5% female and 31.0% male, P\u0026lt; 0.001).\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe purpose of this study was to thoroughly assess cognitive disorders in diabetic elderly people. We concluded in our study population that diabetic patients were more vulnerable to cognitive impairment and that lower physical activity would increase the chances of diabetic patients living with cognitive impairment. It was discovered that hyperglycemia in diabetic patients predisposes them to cognitive impairment the most, and after adjustment of underlying factors such as age, gender, BMI, waist circumference, physical activity, and smoking, we estimated that the incidence of cognitive impairment in diabetic patients increases up to 1.48 times. Furthermore, characteristics such as advanced age, female gender, a positive history of hypertension, widowhood, elevated LDL-C, and even low MET energy expenditure can all be considered risk factors for cognitive impairment. Overall, given diabetics' susceptibility to cognitive impairment, it is reasonable to expect that better glycemic control can suspend the progression of cognitive impairment or even reverse it.\u003c/p\u003e \u003cp\u003eOur study's findings were consistent with those of previous studies. According to the study by Xue et al. [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e], diabetes increased the risk of cognitive impairment by 1.25 to 1.91 times, also fasting glucose levels, HbA1C levels, and insulin resistance index had a significant linear relationship with the incidence and progression of dementia. A study by Gao et al. [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e] propounded the duration from onset of diabetes as a risk factor for dementia among the diabetic population alongside other risk factors like higher levels of age, current smoking, mean waist circumference, duration of diabetes, insulin intake, systolic blood pressure, FBS, HgA1c, and, immunoreactive insulin (IRI). According to Tiwari et al. [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e], cognitive impairment is expected to be 1.3 times more common in diabetics. As reported by Sun et al.[\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e] age, education level, diabetes duration, FBS, and A1C levels all contribute to cognitive impairment in older T2DM. Another study by Jia et al.[\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e] in China considered old age, female gender, low levels of education, widowhood or divorce, smoking history, hypertension, cardiovascular diseases, and ischemic brain diseases as the risk factors for dementia among patients with diabetes. They also illustrated that the prevalence of cognitive impairment increased in diabetics 2.14 times. Consequently, T2DM, especially in poorly controlled conditions, predisposes to disparate stages of cognitive impairment, and some of the conditions associated with diabetes seem to exacerbate that impairment [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. Several studies have been conducted about the pathophysiology and progression of cognitive impairment. Impaired insulin signaling and insulin receptor sensitivity in neurons and dendritic branches in Alzheimer\u0026lsquo;s patients indicate a link between diabetes and cognitive impairment [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]. The second related consequence is mitochondrial dysfunction. Insulin is essential for increasing mitochondrial activity in hippocampal synaptosomes [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. Cerebral mitochondrial function declines in AD patients, which has been linked to cortical hypometabolism and impaired insulin signaling in the brain. In this regard, the pattern of metabolic changes in AD patients has influenced mitochondrial bioenergetic inhibitors [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. Hence, mitochondrial functions after the metabolic regulations are affected by insulin, manipulating cognitive functions [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]. The relationship between diabetic autonomic neuropathy and the incidence of cognitive impairment is a further considerable issue. It has been demonstrated that diabetic autonomic neuropathy is related intimately to hypertension and increased risk of cerebral stroke, both of which are associated with cognitive impairment. Neuroinflammation and brain changes are two other significant concerns raised regarding diabetic cognitive impairment. Accumulation of inflammatory cytokines in the brain has been confirmed in diabetics, which has a significant effect on neuronal damage [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e]. Moreover, NF-kb regulates oxygen radicals and the expression of TNF and variegated interleukins and therefore has an unassailable influence on initiating and activating the inflammatory cascade. High TNF levels and activity inhibit the insulin signaling pathway, which leads to increased production of oxygen radicals or ROS and the progression of cognitive impairment in these individuals [\u003cspan additionalcitationids=\"CR31\" citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eAccording to Sundermann's findings, even prediabetes harms brain metabolism in older men and women. In light of previous findings linking T2DM to reduced brain volume and AD pathology[\u003cspan additionalcitationids=\"CR34 CR35 CR36\" citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e], the findings of this study suggest that functional changes may occur before brain volume changes in the early stages of T2DM[\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. This study also revealed that prediabetes was associated with poorer executive function overall and language performance specifically in the context of mean cognitive impairment (MCI) in women only[\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. Despite this fact that even though these findings and the sex distribution contradict our findings. Dybjer et. al[\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. discovered that pre-diabetes and newly diagnosed diabetes are linked to MCI, and that blood glucose levels, even at the upper end of the normal range, may have a marginally negative effect on cognition. As compared to a healthy individual with normal glucose tolerance, prediabetes or diabetes had slight negative effects on memory, processing speed, and executive functioning[\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]. Since there is no association between prediabetics and cognitive impairment, our findings contradict this article. This could be due to different thresholds for diagnosing prediabetic patients, sample size randomization, or the cognitive impairment assessment system. This should be investigated further in future studies on the matter.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eIn conclusion, we discovered that T2DM, particularly in persistent uncontrolled conditions, has a positive association with cognitive impairment in the elderly population. Aside from diabetes' inflammatory effect on the progression of cognitive disorders, we propose that old age, female gender, history of hypertension, widowhood, increased LDL-C, and even low-calorie consumption are additional risk factors for cognitive impairment. It is also worth noting that in our study, there was no association between prediabetic patients and cognitive impairment.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe study was approved by the Research Ethics Committee of the Endocrinology \u0026amp; Metabolism Research Institute (Ethical code: IR.TUMS.EMRI.REC.1394.0036). Patient consent forms are obtained from patients, and in the case of confirmation of cognitive impairment (based on the Mini-Cog test), consent forms are obtained from patients\u0026apos; families or legal guardians for study participation. Informed consent was obtained from all study participants. \u0026nbsp;All methods were performed in accordance with the relevant guidelines and regulations.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot Applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets used and/or analysed during the current study available from the corresponding author on reasonable request.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eImplementation of this study was sponsored by Tehran University of Medical Sciences (Endocrinology and Metabolism Research Institute).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interest:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors declare that they have no conflict of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFundings:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNone\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor Contributions Statement:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSF,ME,AO,MP,FSH,YSH,SM and ZSH \u0026nbsp;in the study design, writing of the paper, and had significant role in analyzing data. BL participated in critical review. All authors read, provided feedback, and approved the final paper.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003ePal K, Mukadam N, Petersen I, Cooper C: \u003cb\u003eMild cognitive impairment and progression to dementia in people with diabetes\u003c/b\u003e, \u003cb\u003eprediabetes and metabolic syndrome\u003c/b\u003e: \u003cb\u003ea systematic review and meta\u003c/b\u003e-\u003cb\u003eanalysis\u003c/b\u003e. \u003cem\u003eSocial psychiatry and psychiatric epidemiology\u003c/em\u003e 2018, \u003cb\u003e53\u003c/b\u003e(11):1149\u0026ndash;1160.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoran C, Callisaya ML, Srikanth V, Arvanitakis Z: \u003cb\u003eDiabetes therapies for dementia\u003c/b\u003e. Current neurology and neuroscience reports 2019, \u003cb\u003e19\u003c/b\u003e(8):1\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePrince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP: \u003cb\u003eThe global prevalence of dementia\u003c/b\u003e: \u003cb\u003ea systematic review and metaanalysis\u003c/b\u003e. \u003cem\u003eAlzheimer's \u0026amp; dementia\u003c/em\u003e 2013, \u003cb\u003e9\u003c/b\u003e(1):63\u0026ndash;75. e62.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOgurtsova K: \u003cb\u003edRF J.\u003c/b\u003e, Huang Y, Linnenkamp U, Guariguata L, Cho NH, \u003cb\u003eet al\u003c/b\u003e. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015:40\u0026ndash;50.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWong RHX, Scholey A, Howe PRC: \u003cb\u003eAssessing premorbid cognitive ability in adults with type 2 diabetes mellitus\u0026mdash;a review with implications for future intervention studies\u003c/b\u003e. Current diabetes reports 2014, \u003cb\u003e14\u003c/b\u003e(11):547.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGr\u0026uuml;nblatt E, Bartl J, Riederer P: \u003cb\u003eThe link between iron, metabolic syndrome, and Alzheimer\u0026rsquo;s disease\u003c/b\u003e. Journal of Neural Transmission 2011, \u003cb\u003e118\u003c/b\u003e(3):371\u0026ndash;379.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDik MG, Jonker C, Comijs HC, Deeg DJ, Kok A, Yaffe K, Penninx BW: \u003cb\u003eContribution of metabolic syndrome components to cognition in older individuals\u003c/b\u003e. Diabetes care 2007, \u003cb\u003e30\u003c/b\u003e(10):2655\u0026ndash;2660.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePalta P, Schneider AL, Biessels GJ, Touradji P, Hill-Briggs F: \u003cb\u003eMagnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains\u003c/b\u003e. Journal of the International Neuropsychological Society 2014, \u003cb\u003e20\u003c/b\u003e(3):278\u0026ndash;291.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMonette MC, Baird A, Jackson DL: \u003cb\u003eA meta-analysis of cognitive functioning in nondemented adults with type 2 diabetes mellitus\u003c/b\u003e. Canadian journal of diabetes 2014, \u003cb\u003e38\u003c/b\u003e(6):401\u0026ndash;408.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRawlings AM, Sharrett AR, Schneider AL, Coresh J, Albert M, Couper D, Griswold M, Gottesman RF, Wagenknecht LE, Windham BG: \u003cb\u003eDiabetes in midlife and cognitive change over 20 years: a cohort study\u003c/b\u003e. Annals of internal medicine 2014, \u003cb\u003e161\u003c/b\u003e(11):785\u0026ndash;793.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChatterjee S, Peters SA, Woodward M, Mejia Arango S, Batty GD, Beckett N, Beiser A, Borenstein AR, Crane PK, Haan M \u003cem\u003eet al\u003c/em\u003e: \u003cb\u003eType 2 Diabetes as a Risk Factor for Dementia in Women Compared With Men: A Pooled Analysis of 2.3 Million People Comprising More Than 100,000 Cases of Dementia\u003c/b\u003e. Diabetes Care 2016, \u003cb\u003e39\u003c/b\u003e(2):300\u0026ndash;307.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ede la Monte SM: \u003cb\u003eBrain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease\u003c/b\u003e. Curr Alzheimer Res 2012, \u003cb\u003e9\u003c/b\u003e(1):35\u0026ndash;66.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAkter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB: \u003cb\u003eDiabetes mellitus and Alzheimer's disease: shared pathology and treatment?\u003c/b\u003e Br J Clin Pharmacol 2011, \u003cb\u003e71\u003c/b\u003e(3):365\u0026ndash;376.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOtt A, Stolk RP, van Harskamp F, Pols HAP, Hofman A, Breteler MMB: \u003cb\u003eDiabetes mellitus and the risk of dementia\u003c/b\u003e. Neurology 1999, \u003cb\u003e53\u003c/b\u003e(9):1937.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eN S, Karan: \u003cb\u003eAssessment of the cognitive status in diabetes mellitus\u003c/b\u003e. J Clin Diagn Res 2012, \u003cb\u003e6\u003c/b\u003e(10):1658\u0026ndash;1662.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLuchsinger JA: \u003cb\u003eAdiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective\u003c/b\u003e. Eur J Pharmacol 2008, \u003cb\u003e585\u003c/b\u003e(1):119\u0026ndash;129.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCrane PK, Walker R, Hubbard RA, Li G, Nathan DM, Zheng H, Haneuse S, Craft S, Montine TJ, Kahn SE \u003cem\u003eet al\u003c/em\u003e: \u003cb\u003eGlucose levels and risk of dementia\u003c/b\u003e. N Engl J Med 2013, \u003cb\u003e369\u003c/b\u003e(6):540\u0026ndash;548.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOhara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, Kanba S, Kiyohara Y: \u003cb\u003eGlucose tolerance status and risk of dementia in the community: the Hisayama study\u003c/b\u003e. Neurology 2011, \u003cb\u003e77\u003c/b\u003e(12):1126\u0026ndash;1134.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIka K, Suzuki E, Mitsuhashi T, Takao S, Doi H: \u003cb\u003eShift work and diabetes mellitus among male workers in Japan: does the intensity of shift work matter?\u003c/b\u003e Acta Med Okayama 2013, \u003cb\u003e67\u003c/b\u003e(1):25\u0026ndash;33.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXue M, Xu W, Ou YN, Cao XP, Tan MS, Tan L, Yu JT: \u003cb\u003eDiabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies\u003c/b\u003e. Ageing Res Rev 2019, \u003cb\u003e55\u003c/b\u003e:100944.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGao Y, Xiao Y, Miao R, Zhao J, Cui M, Huang G, Fei M: \u003cb\u003eThe prevalence of mild cognitive impairment with type 2 diabetes mellitus among elderly people in China: A cross-sectional study\u003c/b\u003e. Arch Gerontol Geriatr 2016, \u003cb\u003e62\u003c/b\u003e:138\u0026ndash;142.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTiwari SC, Tripathi RK, Farooqi SA, Kumar R, Srivastava G, Kumar A: \u003cb\u003eDiabetes mellitus: A risk factor for cognitive impairment amongst urban older adults\u003c/b\u003e. Ind Psychiatry J 2012, \u003cb\u003e21\u003c/b\u003e(1):44\u0026ndash;48.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSun L, Diao X, Gang X, Lv Y, Zhao X, Yang S, Gao Y, Wang G: \u003cb\u003eRisk Factors for Cognitive Impairment in Patients with Type 2 Diabetes\u003c/b\u003e. J Diabetes Res 2020, \u003cb\u003e2020\u003c/b\u003e:4591938.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJia HH, Liu L, Huo GX, Wang RQ, Zhou YQ, Yang LY: \u003cb\u003eA qualitative study of the cognitive behavioral intention of patients with diabetes in rural China who have experienced delayed diagnosis and treatment\u003c/b\u003e. BMC Public Health 2020, \u003cb\u003e20\u003c/b\u003e(1):478.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCalvo-Ochoa E, Arias C: \u003cb\u003eCellular and metabolic alterations in the hippocampus caused by insulin signalling dysfunction and its association with cognitive impairment during aging and Alzheimer's disease: studies in animal models\u003c/b\u003e. Diabetes Metab Res Rev 2015, \u003cb\u003e31\u003c/b\u003e(1):1\u0026ndash;13.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHeras-Sandoval D, Ferrera P, Arias C: \u003cb\u003eAmyloid-β protein modulates insulin signaling in presynaptic terminals\u003c/b\u003e. Neurochemical research 2012, \u003cb\u003e37\u003c/b\u003e(9):1879\u0026ndash;1885.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChoi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW: \u003cb\u003eIdentification of oxidized plasma proteins in Alzheimer's disease\u003c/b\u003e. Biochemical and biophysical research communications 2002, \u003cb\u003e293\u003c/b\u003e(5):1566\u0026ndash;1570.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLu T, Pan Y, Kao S, Li C, Kohane I: \u003cb\u003echan\u003c/b\u003e, J.; Yankner, \u003cb\u003eBA\u003c/b\u003e. \u003cem\u003eNature\u003c/em\u003e 2004, \u003cb\u003e429\u003c/b\u003e:883.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGaspar JM, Baptista FI, Macedo MP, Ambrosio AF: \u003cb\u003eInside the diabetic brain: role of different players involved in cognitive decline\u003c/b\u003e. ACS Chemical Neuroscience 2016, \u003cb\u003e7\u003c/b\u003e(2):131\u0026ndash;142.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang J, Li G, Wang Z, Zhang X, Yao L, Wang F, Liu S, Yin J, Ling E-A, Wang L: \u003cb\u003eHigh glucose-induced expression of inflammatory cytokines and reactive oxygen species in cultured astrocytes\u003c/b\u003e. Neuroscience 2012, \u003cb\u003e202\u003c/b\u003e:58\u0026ndash;68.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSima AA: \u003cb\u003eEncephalopathies: the emerging diabetic complications\u003c/b\u003e. Acta diabetologica 2010, \u003cb\u003e47\u003c/b\u003e(4):279\u0026ndash;293.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKuhad A, Bishnoi M, Tiwari V, Chopra K: \u003cb\u003eSuppression of NF-κβ signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits\u003c/b\u003e. Pharmacology Biochemistry and Behavior 2009, \u003cb\u003e92\u003c/b\u003e(2):251\u0026ndash;259.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoran C, Phan TG, Chen J, Blizzard L, Beare R, Venn A, M\u0026uuml;nch G, Wood AG, Forbes J, Greenaway TM: \u003cb\u003eBrain atrophy in type 2 diabetes: regional distribution and influence on cognition\u003c/b\u003e. Diabetes care 2013, \u003cb\u003e36\u003c/b\u003e(12):4036\u0026ndash;4042.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V: \u003cb\u003eType 2 diabetes mellitus and biomarkers of neurodegeneration\u003c/b\u003e. Neurology 2015, \u003cb\u003e85\u003c/b\u003e(13):1123\u0026ndash;1130.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBiessels GJ, Reijmer YD: \u003cb\u003eBrain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI?\u003c/b\u003e Diabetes 2014, \u003cb\u003e63\u003c/b\u003e(7):2244\u0026ndash;2252.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCallisaya ML, Beare R, Moran C, Phan T, Wang W, Srikanth VK: \u003cb\u003eType 2 diabetes mellitus, brain atrophy and cognitive decline in older people: a longitudinal study\u003c/b\u003e. Diabetologia 2019, \u003cb\u003e62\u003c/b\u003e(3):448\u0026ndash;458.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBangen KJ, Werhane ML, Weigand AJ, Edmonds EC, Delano-Wood L, Thomas KR, Nation DA, Evangelista ND, Clark AL, Liu TT: \u003cb\u003eReduced regional cerebral blood flow relates to poorer cognition in older adults with type 2 diabetes\u003c/b\u003e. Frontiers in aging neuroscience 2018:270.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSundermann EE, Thomas KR, Bangen KJ, Weigand AJ, Eppig JS, Edmonds EC, Wong CG, Bondi MW, Delano-Wood L: \u003cb\u003ePrediabetes Is Associated With Brain Hypometabolism and Cognitive Decline in a Sex-Dependent Manner: A Longitudinal Study of Nondemented Older Adults\u003c/b\u003e. Frontiers in Neurology 2021, \u003cb\u003e12\u003c/b\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDybjer E, Nilsson PM, Engstr\u0026ouml;m G, Helmer C, N\u0026auml;gga K: \u003cb\u003ePre-diabetes and diabetes are independently associated with adverse cognitive test results: a cross-sectional, population-based study\u003c/b\u003e. BMC endocrine disorders 2018, \u003cb\u003e18\u003c/b\u003e(1):1\u0026ndash;10.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTable 1- Characteristics of the participants\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003eTotal Participants\u003c/p\u003e\n \u003cp\u003eN=1533\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003enormal cognition\u003c/p\u003e\n \u003cp\u003eN = 840\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003eImpaired cognition\u003c/p\u003e\n \u003cp\u003eN = 693\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u003cem\u003eP-value\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eAge, year\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e69.2\u0026plusmn;6.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e67.6\u0026plusmn;5.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e71.2\u0026plusmn;7.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eSex, %\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;female\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;male\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e750 (48.9)\u003c/p\u003e\n \u003cp\u003e783 (51.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e301 (35.8)\u003c/p\u003e\n \u003cp\u003e539 (64.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e449 (64.8)\u003c/p\u003e\n \u003cp\u003e244 (35.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eBMI, kg/m\u003csup\u003e2\u003c/sup\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e30.9\u0026plusmn;5.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eWC, cm\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e98.5\u0026plusmn;11.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e98.5\u0026plusmn;11.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e98.4\u0026plusmn;12.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e0.917\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eEducation, %\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Illiterate\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Primary School\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;High School\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Diploma\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Academic\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e563 (36.7)\u003c/p\u003e\n \u003cp\u003e540 (35.2)\u003c/p\u003e\n \u003cp\u003e136 (8.9)\u003c/p\u003e\n \u003cp\u003e196 (12.8)\u003c/p\u003e\n \u003cp\u003e98 (6.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e320 (38.1)\u003c/p\u003e\n \u003cp\u003e278 (33.1)\u003c/p\u003e\n \u003cp\u003e82 (9.8)\u003c/p\u003e\n \u003cp\u003e102 (12.1)\u003c/p\u003e\n \u003cp\u003e58 (6.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e243 (35.1)\u003c/p\u003e\n \u003cp\u003e262 (37.8)\u003c/p\u003e\n \u003cp\u003e54 (7.8)\u003c/p\u003e\n \u003cp\u003e94 (13.6)\u003c/p\u003e\n \u003cp\u003e40 (5.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e0.173\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eMarital status, %\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Single\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Married\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Divorced\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Widow- Widower\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e13 (0.8)\u003c/p\u003e\n \u003cp\u003e1195 (77.9)\u003c/p\u003e\n \u003cp\u003e13 (0.8)\u003c/p\u003e\n \u003cp\u003e312 (20.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e6 (0.7)\u003c/p\u003e\n \u003cp\u003e731 (87.0)\u003c/p\u003e\n \u003cp\u003e7 (0.8)\u003c/p\u003e\n \u003cp\u003e96 (11.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e7 (1.0)\u003c/p\u003e\n \u003cp\u003e464 (67.0)\u003c/p\u003e\n \u003cp\u003e6 (0.9)\u003c/p\u003e\n \u003cp\u003e216 (31.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eSmoking, %\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Occasionally smoker\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Current smoker\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e66 (4.3)\u003c/p\u003e\n \u003cp\u003e256 (16.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e30 (3.6)\u003c/p\u003e\n \u003cp\u003e132 (15.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e36 (5.2)\u003c/p\u003e\n \u003cp\u003e124 (17.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e0.132\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eGlycemia, %\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Normo-glycemia\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Prediabetes\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Diabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e792 (51.7)\u003c/p\u003e\n \u003cp\u003e256 (16.7)\u003c/p\u003e\n \u003cp\u003e485 (31.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e464 (55.2)\u003c/p\u003e\n \u003cp\u003e144 (17.1)\u003c/p\u003e\n \u003cp\u003e232 (27.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e328 (47.3)\u003c/p\u003e\n \u003cp\u003e112 (16.2)\u003c/p\u003e\n \u003cp\u003e253 (36.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eHypertension, %\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e1084 (70.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e573 (68.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e511 (73.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.018\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eHbA1c, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e5.6\u0026plusmn;1.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e5.5\u0026plusmn;1.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e5.8\u0026plusmn;1.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.004\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;normal glycemia\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e4.7\u0026plusmn;0 .5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e4.8\u0026plusmn;0 .4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e4.7\u0026plusmn;0 .5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e0.241\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Prediabetes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e5.6\u0026plusmn;0 .7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e5.5\u0026plusmn;0 .7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e5.6\u0026plusmn;0 .6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e0.148\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Diabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e7.1\u0026plusmn; 1.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e7.1\u0026plusmn; 1.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e7.2\u0026plusmn; 1.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e0.754\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eFBS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e105.0\u0026plusmn;41.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e102.1\u0026plusmn;35.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e108.7\u0026plusmn;47.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.002\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;normal glycemia\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e85.7\u0026plusmn;7.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e86.1\u0026plusmn;7.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e85.0\u0026plusmn;8.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e0.054\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Prediabetes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e101.0\u0026plusmn;14.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e101.3\u0026plusmn;14.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e100.6\u0026plusmn;13.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e0.672\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003e\u0026nbsp; \u0026nbsp; \u0026nbsp;Diabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e138.9\u0026plusmn;58.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e134.5\u0026plusmn;51.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e143.1\u0026plusmn;63.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e0.103\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eTriglyceride, mg/dl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e133.8\u0026plusmn;67.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e133.6\u0026plusmn;69.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e134.1\u0026plusmn;63.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e0.871\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eLDL, mg/dl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e109.1\u0026plusmn;37.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e107.2\u0026plusmn;37.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e111.5\u0026plusmn;37.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.028\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eHDL, mg/dl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e45.7\u0026plusmn;11.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e45.5\u0026plusmn;11.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e45.9\u0026plusmn;10.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e0.522\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"31.28930817610063%\"\u003e\n \u003cp\u003eTotal weekly MET (kcal/kg/day)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"21.540880503144653%\"\u003e\n \u003cp\u003e30.9\u0026plusmn;5.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e31.7\u0026plusmn;5.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"18.867924528301888%\"\u003e\n \u003cp\u003e29.9\u0026plusmn;4.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.433962264150944%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eWC: waist circumference; HbA1c: hemoglobin A1c; FBS: fasting blood sugar; LDL: low-density lipoprotein; HDL: high-density lipoprotein\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 2- Characteristics of the participants\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\" width=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" valign=\"top\" width=\"16.115261472785484%\"\u003e\n \u003cp\u003eVariable\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"26.894343649946638%\"\u003e\n \u003cp\u003eNormo-glycemia\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"28.17502668089648%\"\u003e\n \u003cp\u003ePre-diabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"28.8153681963714%\"\u003e\n \u003cp\u003eDiabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"11.450381679389313%\"\u003e\n \u003cp\u003enormal C\u003c/p\u003e\n \u003cp\u003eN = 464\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.450381679389313%\"\u003e\n \u003cp\u003eCI\u003c/p\u003e\n \u003cp\u003eN = 328\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.16030534351145%\"\u003e\n \u003cp\u003e\u003cem\u003eP-value\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.450381679389313%\"\u003e\n \u003cp\u003enormal C\u003c/p\u003e\n \u003cp\u003eN = 144\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"12.213740458015268%\"\u003e\n \u003cp\u003eCI\u003c/p\u003e\n \u003cp\u003eN = 112\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.923664122137405%\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.450381679389313%\"\u003e\n \u003cp\u003enormal C\u003c/p\u003e\n \u003cp\u003eN = 232\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.450381679389313%\"\u003e\n \u003cp\u003eCI\u003c/p\u003e\n \u003cp\u003eN = 253\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.450381679389313%\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"16.115261472785484%\"\u003e\n \u003cp\u003eAge, year\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e67.5\u0026plusmn;5.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e71.9\u0026plusmn;7.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.68409818569904%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e68.6\u0026plusmn;6.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"10.245464247598719%\"\u003e\n \u003cp\u003e72.2\u0026plusmn;7.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.32443970117396%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e67.1\u0026plusmn;4.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e69.8\u0026plusmn; 6.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"16.115261472785484%\"\u003e\n \u003cp\u003eWC/cm\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e96.9\u0026plusmn;11.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e95.2\u0026plusmn;12.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.68409818569904%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.044\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e100.0\u0026plusmn;10.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"10.245464247598719%\"\u003e\n \u003cp\u003e100.0\u0026plusmn;13.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.32443970117396%\"\u003e\n \u003cp\u003e0.979\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e100.6\u0026plusmn;11.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e101.9\u0026plusmn;11.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e0.218\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"16.115261472785484%\"\u003e\n \u003cp\u003eHbA1c, %\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e4.8\u0026plusmn;0 .4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e4.7\u0026plusmn;0 .5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.68409818569904%\"\u003e\n \u003cp\u003e0.241\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e5.5\u0026plusmn;0 .7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"10.245464247598719%\"\u003e\n \u003cp\u003e5.6\u0026plusmn;0 .6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.32443970117396%\"\u003e\n \u003cp\u003e0.148\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e7.1\u0026plusmn; 1.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e7.2\u0026plusmn; 1.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e0.754\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"16.115261472785484%\"\u003e\n \u003cp\u003eFBS, mg/dl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e86.1\u0026plusmn;7.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e85.0\u0026plusmn;8.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.68409818569904%\"\u003e\n \u003cp\u003e0.054\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e101.3\u0026plusmn;14.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"10.245464247598719%\"\u003e\n \u003cp\u003e100.6\u0026plusmn;13.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.32443970117396%\"\u003e\n \u003cp\u003e0.672\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e134.5\u0026plusmn;51.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e143.1\u0026plusmn;63.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e0.103\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"16.115261472785484%\"\u003e\n \u003cp\u003eTriglyceride, mg/dl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e125.8\u0026plusmn;61.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e118.3\u0026plusmn;52.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.68409818569904%\"\u003e\n \u003cp\u003e0.072\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e143.6\u0026plusmn;76.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"10.245464247598719%\"\u003e\n \u003cp\u003e152.0\u0026plusmn;80.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.32443970117396%\"\u003e\n \u003cp\u003e0.391\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e142.8\u0026plusmn;80.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e146.7\u0026plusmn;64.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e0.559\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"16.115261472785484%\"\u003e\n \u003cp\u003eLDL, mg/dl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e114.4\u0026plusmn;34.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e116.0\u0026plusmn;35.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.68409818569904%\"\u003e\n \u003cp\u003e0.524\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e111.3\u0026plusmn;44.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"10.245464247598719%\"\u003e\n \u003cp\u003e118.8\u0026plusmn;38.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.32443970117396%\"\u003e\n \u003cp\u003e0.158\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e90.3\u0026plusmn;32.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e102.3\u0026plusmn;37.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"16.115261472785484%\"\u003e\n \u003cp\u003eHDL, mg/dl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e46.2\u0026plusmn;11.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e47.2\u0026plusmn;11.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.68409818569904%\"\u003e\n \u003cp\u003e0.198\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e45.1\u0026plusmn;11.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"10.245464247598719%\"\u003e\n \u003cp\u003e46.3\u0026plusmn;10.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.32443970117396%\"\u003e\n \u003cp\u003e0.346\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e44.3\u0026plusmn; 11.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e43.8\u0026plusmn;10.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e0.618\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"16.115261472785484%\"\u003e\n \u003cp\u003eHemoglobin, g/dl\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e14.6\u0026plusmn;1.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e14.5\u0026plusmn; 1.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.68409818569904%\"\u003e\n \u003cp\u003e0.121\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e14.7\u0026plusmn;1.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"10.245464247598719%\"\u003e\n \u003cp\u003e14.1\u0026plusmn;2.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.32443970117396%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.010\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e14.2\u0026plusmn;1.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e14.2\u0026plusmn;1.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e0.785\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"16.115261472785484%\"\u003e\n \u003cp\u003eTotal weekly MET (kcal/kg/day)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e31.9\u0026plusmn;5.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e30.3\u0026plusmn;5.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.68409818569904%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e31.5\u0026plusmn;5.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"10.245464247598719%\"\u003e\n \u003cp\u003e29.2\u0026plusmn;4.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.32443970117396%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e31.3\u0026plusmn;4.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e29.5\u0026plusmn;4.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"9.6051227321238%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eWC: waist circumference; HbA1c: hemoglobin A1c; FBS: fasting blood sugar; LDL: low-density lipoprotein; HDL: high-density lipoprotein\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 3- Associations of possibly related variables with cognitive impairment\u0026nbsp;\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" valign=\"top\" width=\"18.220338983050848%\"\u003e\n \u003cp\u003eVariable\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"27.824858757062145%\"\u003e\n \u003cp\u003eNormal (n=780)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"27.401129943502823%\"\u003e\n \u003cp\u003ePre-diabetes (n=245)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"3\" valign=\"top\" width=\"26.55367231638418%\"\u003e\n \u003cp\u003eDiabetes (n=480)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"8.304498269896193%\"\u003e\n \u003cp\u003eOR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.705882352941176%\"\u003e\n \u003cp\u003e95% CI OR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"10.899653979238755%\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.996539792387543%\"\u003e\n \u003cp\u003eOR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"13.667820069204152%\"\u003e\n \u003cp\u003e95% CI OR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"10.899653979238755%\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.304498269896193%\"\u003e\n \u003cp\u003eOR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"13.667820069204152%\"\u003e\n \u003cp\u003e95% CI OR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"10.55363321799308%\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"18.246110325318245%\"\u003e\n \u003cp\u003eAge\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e1.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"12.022630834512023%\"\u003e\n \u003cp\u003e1.09- 1.15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.355021216407355%\"\u003e\n \u003cp\u003e1.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e1.01-1.11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.007\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e1.09\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e1.05-1.13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.628005657708629%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"18.246110325318245%\"\u003e\n \u003cp\u003eSex\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e0.21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"12.022630834512023%\"\u003e\n \u003cp\u003e0.15- 0.30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.355021216407355%\"\u003e\n \u003cp\u003e0.33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.19-0.59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e\u0026lt;0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e0.33\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.22-0.50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.628005657708629%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"18.246110325318245%\"\u003e\n \u003cp\u003eBMI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e0.63\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"12.022630834512023%\"\u003e\n \u003cp\u003e0.29- 1.36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.248\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.355021216407355%\"\u003e\n \u003cp\u003e2.15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.58-7.89\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.248\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e2.39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.83-6.81\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.628005657708629%\"\u003e\n \u003cp\u003e0.103\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"18.246110325318245%\"\u003e\n \u003cp\u003eWC\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e0.99\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"12.022630834512023%\"\u003e\n \u003cp\u003e0.98-1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.385\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.355021216407355%\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.98-1.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.646\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e1.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.99-1.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.628005657708629%\"\u003e\n \u003cp\u003e0.261\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"18.246110325318245%\"\u003e\n \u003cp\u003ePhysical activity\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e0.98\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"12.022630834512023%\"\u003e\n \u003cp\u003e0.95-1.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.377\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.355021216407355%\"\u003e\n \u003cp\u003e0.93\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.87-1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.070\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e0.94\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.90-0.99\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.628005657708629%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.018\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"18.246110325318245%\"\u003e\n \u003cp\u003eSmoking\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e1.32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"12.022630834512023%\"\u003e\n \u003cp\u003e1.07-1.62\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.007\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.355021216407355%\"\u003e\n \u003cp\u003e0.78\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.53-1.17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.245\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e1.25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.93-1.68\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.628005657708629%\"\u003e\n \u003cp\u003e0.135\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"18.246110325318245%\"\u003e\n \u003cp\u003eFBS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e0.99\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"12.022630834512023%\"\u003e\n \u003cp\u003e0.97-1.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.396\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.355021216407355%\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.98-1.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.749\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e1.00-1.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.628005657708629%\"\u003e\n \u003cp\u003e0.050\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"18.246110325318245%\"\u003e\n \u003cp\u003eTriglyceride\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e0.99\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"12.022630834512023%\"\u003e\n \u003cp\u003e0.99-1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.138\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.355021216407355%\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.99-1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.090\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e0.99\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.99-1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.628005657708629%\"\u003e\n \u003cp\u003e0.662\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"18.246110325318245%\"\u003e\n \u003cp\u003eLDL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e0.99\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"12.022630834512023%\"\u003e\n \u003cp\u003e0.99-1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.430\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"7.355021216407355%\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e0.99-1.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.910891089108912%\"\u003e\n \u003cp\u003e0.319\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"6.789250353606789%\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.173974540311175%\"\u003e\n \u003cp\u003e1.00-1.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"8.628005657708629%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.006\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eBMI: body mass index; WC: waist circumference; FBS: fasting blood sugar; LDL: low-density lipoprotein;\u003c/p\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 4- Associations of pre-diabetes and diabetes with cognitive impairment\u003c/p\u003e\n\u003ctable border=\"1\" cellpadding=\"0\" cellspacing=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003eOR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e95% CI OR\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e-value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\" valign=\"top\" width=\"100%\"\u003e\n \u003cp\u003eUnadjusted model\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003ePre-diabetes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e1.10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e0.82-1.46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e0.510\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003eDiabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e1.54\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e1.22-1.93\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"4\" valign=\"top\" width=\"100%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003cp\u003eAdjusted models\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003ePre-diabetes\u003csup\u003e1\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e0.99\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e0.74-1.34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e0.999\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003eDiabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e1.37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e1.08-1.73\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.009\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003ePre-diabetes\u003csup\u003e2\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e0.91\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e0.66- 1.24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e0.554\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003eDiabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e1.51\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e1.18- 1.94\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.001\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003ePre-diabetes\u003csup\u003e3\u003c/sup\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e0.96\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e0.70-1.32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e0.826\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003eDiabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e1.59\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e1.24-2.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.000\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003ePre-diabetes\u003csup\u003e4\u003c/sup\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e0.92\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e0.67-1.27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e0.637\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003eDiabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e1.46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e1.12-1.88\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.004\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003ePre-diabetes\u003csup\u003e5\u003c/sup\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e0.92\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e0.66-1.27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e0.612\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003eDiabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e1.50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e1.16-1.94\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.002\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003ePre-diabetes\u003csup\u003e6\u003c/sup\u003e \u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e0.91\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e0.66-1.26\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e0.603\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003eDiabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e1.51\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e1.16-1.96\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.002\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003ePre-diabetes\u003csup\u003e7\u003c/sup\u003e \u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e0.92\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e0.67-1.27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e0.630\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" width=\"48.497854077253216%\"\u003e\n \u003cp\u003eDiabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"11.587982832618026%\"\u003e\n \u003cp\u003e1.48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"25.751072961373392%\"\u003e\n \u003cp\u003e1.14-1.91\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" width=\"14.163090128755364%\"\u003e\n \u003cp\u003e\u003cstrong\u003e0.003\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eOR: Odds Ratio, CI: Confidence Interval\u003c/p\u003e\n\u003cp\u003e1 Adjusted for age, sex\u003c/p\u003e\n\u003cp\u003e2 Adjusted for age, sex\u003c/p\u003e\n\u003cp\u003e3 Adjusted for age, sex, BMI\u003c/p\u003e\n\u003cp\u003e4 Adjusted for age, sex, BMI, WC, physical activity\u003c/p\u003e\n\u003cp\u003e5 Adjusted for age, sex, BMI, WC, physical activity, serum hemoglobin\u003c/p\u003e\n\u003cp\u003e6 Adjusted for age, sex, BMI, WC, physical activity, serum hemoglobin, and smoking\u003c/p\u003e\n\u003cp\u003e7 Adjusted for age, sex, BMI, WC, physical activity, smoking\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Pre-diabetes, Diabetes, Cognitive Impairment, Aged","lastPublishedDoi":"10.21203/rs.3.rs-1658783/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1658783/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eUncontrolled hyperglycemia is one of the risk factors for cognitive disorders. By this finding, both type 1 and type 2 diabetes may predispose to cognitive impairment in poorly controlled cases. The current large-scale study is aimed at cognitive impairments in diabetic and non-diabetic older adults separately.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eThis is a cross-sectional study from phase 2 of the Bushehr elderly health program (BEHP). Mini-cog and categorical verbal fluency tests (CFTs) were used to assess cognitive function. Patients were classified as non-diabetics, pre-diabetics, or diabetics based on the diagnostic criteria for diabetes mellitus (DM). To compare the means of the two groups, we used the t-test or the Mann-Whitney test. Multivariable logistic regression models were also used to determine the association between pre-diabetes or DM and cognitive impairment.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eSix hundred and ninety-three (45.2%) out of 1533 participants were ascertained to be cognitively impaired. The average hemoglobin A1C was higher in diabetic patients with cognitive impairment compared to those without cognitive impairment. (5.8\u0026thinsp;\u0026plusmn;\u0026thinsp;1.6% vs. 5.5\u0026thinsp;\u0026plusmn;\u0026thinsp;1.4%, P\u0026thinsp;=\u0026thinsp;0.004). Besides, the mean blood glucose levels were found to be more elevated in cognitively impaired cases (108.0\u0026thinsp;\u0026plusmn;\u0026thinsp;47.4 mg/dL vs. 102.1\u0026thinsp;\u0026plusmn;\u0026thinsp;0.35 mg/dL, P\u0026thinsp;=\u0026thinsp;0.002). After adjusting for age, gender, body mass index(BMI), waist circumference, amount of physical activity, and smoking, the multivariable logistic regression model, declared an association between diabetes and cognitive impairment (OR\u0026thinsp;=\u0026thinsp;1.48, P\u0026thinsp;=\u0026thinsp;0.003). Older patients, females, widows, and patients with elevated LDL-Cs and blood pressure are also more vulnerable to cognitive impairment.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eIn the BEHP, there is a positive association between cognitive impairment and DM, notably in long-term, poorly controlled cases, whereas no association was found among pre-diabetics in our elderly study populations.\u003c/p\u003e","manuscriptTitle":"Association between pre-diabetes or diabetes and cognitive impairment in a -community dwelling older population: Bushehr Elderly Health (BEH) program","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-06-06 18:26:16","doi":"10.21203/rs.3.rs-1658783/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"260c48a9-2a1b-46a4-ae93-1ecfff60c84f","owner":[],"postedDate":"June 6th, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2024-06-24T11:30:29+00:00","versionOfRecord":{"articleIdentity":"rs-1658783","link":"https://doi.org/10.1007/s40200-023-01325-y","journal":{"identity":"journal-of-diabetes-and-metabolic-disorders","isVorOnly":false,"title":"Journal of Diabetes \u0026 Metabolic Disorders"},"publishedOn":"2023-10-18 11:30:29","publishedOnDateReadable":"October 18th, 2023"},"versionCreatedAt":"2022-06-06 18:26:16","video":"","vorDoi":"10.1007/s40200-023-01325-y","vorDoiUrl":"https://doi.org/10.1007/s40200-023-01325-y","workflowStages":[]},"version":"v1","identity":"rs-1658783","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1658783","identity":"rs-1658783","version":["v1"]},"buildId":"7rjqhiLT3MXkJMwkYKINL","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}